Diadema Partners LP Crispr Therapeutics Ag Transaction History
Diadema Partners LP
- $233 Billion
- Q4 2024
A detailed history of Diadema Partners LP transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Diadema Partners LP holds 190,800 shares of CRSP stock, worth $9.62 Million. This represents 3.22% of its overall portfolio holdings.
Number of Shares
190,800Holding current value
$9.62 Million% of portfolio
3.22%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding CRSP
# of Institutions
484Shares Held
64.1MCall Options Held
1.64MPut Options Held
1.93M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$453 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$441 Million0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.81MShares$192 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$140 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.75MShares$138 Million0.07% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.93B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....